FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:563-572 February 5, 2009 Number 6 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Supplementary Material Editorial by Mayer, R. J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Fluoropyrimidine-based chemotherapy plus the anti–vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorectal cancer. We studied the effect of adding the anti–epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer.

Methods We randomly assigned 755 patients with previously untreated metastatic colorectal cancer to capecitabine, oxaliplatin, and bevacizumab (CB regimen, 378 patients) or the same regimen plus weekly cetuximab (CBC regimen, 377 patients). The primary end point was progression-free survival. The mutation status of the KRAS gene was evaluated as a predictor of outcome.

Results The median progression-free survival was 10.7 months in the CB group and 9.4 in the CBC group (P=0.01). Quality-of-life scores were lower in the CBC group. The overall survival and response rates did not differ significantly in the two groups. Treated patients in the CBC group had more grade 3 or 4 adverse events, which were attributed to cetuximab-related adverse cutaneous effects. Patients treated with cetuximab who had tumors bearing a mutated KRAS gene had significantly decreased progression-free survival as compared with cetuximab-treated patients with wild-type–KRAS tumors or patients with mutated-KRAS tumors in the CB group.

Conclusions The addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab resulted in significantly shorter progression-free survival and inferior quality of life. Mutation status of the KRAS gene was a predictor of outcome in the cetuximab group. (ClinicalTrials.gov number, NCT00208546 [ClinicalTrials.gov] .)

Source Information

From Radboud University Nijmegen Medical Center, Nijmegen (J.T., M.K., J.R.D., M.E.V.-B., J.H.J.M.K., C.J.A.P.); the Netherlands Cancer Institute, Amsterdam (A.C., N.F.A., O.D.); Meander Medical Center, Amersfoort (C.J.R.); Catharina Hospital, Eindhoven (G.J.M.C.); Spaarne Hospital, Hoofddorp (J.G.S.); Maasland Hospital, Sittard (F.L.G.E.); Bernhoven Hospital, Oss (A.H.V.); the Free University Medical Center, Amsterdam (C.J.G.); Jeroen Bosch Hospital, `s-Hertogenbosch (H.A.M.S.); the Amsterdam Medical Center, Amsterdam (D.J.R.); University Medical Center, Utrecht (E.E.V.); and the Comprehensive Cancer Center East, Nijmegen (L.M.) — all in the Netherlands.

Address reprint requests to Dr. Punt at the Department of Medical Oncology, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands, or at c.punt{at}onco.umcn.nl.

Full Text of this Article

Related Letters:

Chemotherapy and Immunotherapy in Metastatic Colorectal Cancer
Pohlmann P. R., Mernaugh R. L., Goff L. W., Frati L., Codacci-Pisanelli G., Copur M. S., Norvell M., Obermiller A., Loupakis F., Di Maio M., Falcone A., Punt C. J.A., Tol J.
Extract | Full Text | PDF  
N Engl J Med 2009; 360:2134-2136, May 14, 2009. Correspondence

This article has been cited by other articles:

• Tol, J., Koopman, M., Miller, M. C., Tibbe, A., Cats, A., Creemers, G. J. M., Vos, A. H., Nagtegaal, I. D., Terstappen, L. W. M. M., Punt, C. J. A. (2009). Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 0: mdp463v1-mdp463 [Abstract] [Full Text]  
• Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., Bardelli, A. (2009). Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer. JNCI J Natl Cancer Inst 101: 1308-1324 [Abstract] [Full Text]  
• Holdhoff, M., Schmidt, K., Donehower, R., Diaz, L. A. Jr (2009). Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations. JNCI J Natl Cancer Inst 101: 1284-1285 [Full Text]  
• Fojo, T., Grady, C. (2009). How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. JNCI J Natl Cancer Inst 101: 1044-1048 [Abstract] [Full Text]  
• Tol, J., Nagtegaal, I. D., Punt, C. J.A. (2009). BRAF mutation in metastatic colorectal cancer.. NEJM 361: 98-99 [Full Text]  
• Cohen, S. J., Punt, C. J. A., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M. A., Mitchell, E., Miller, M. C., Doyle, G. V., Tissing, H., Terstappen, L. W. M. M., Meropol, N. J. (2009). Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20: 1223-1229 [Abstract] [Full Text]  
• Ronellenfitsch, M. W., Brucker, D. P., Burger, M. C., Wolking, S., Tritschler, F., Rieger, J., Wick, W., Weller, M., Steinbach, J. P. (2009). Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Brain 132: 1509-1522 [Abstract] [Full Text]  
• Pohlmann, P. R., Mernaugh, R. L., Goff, L. W., Frati, L., Codacci-Pisanelli, G., Copur, M. S., Norvell, M., Obermiller, A., Loupakis, F., Di Maio, M., Falcone, A., Punt, C. J.A., Tol, J. (2009). Chemotherapy and Immunotherapy in Metastatic Colorectal Cancer. NEJM 360: 2134-2136 [Full Text]  
• (2009). Cetuximab plus Bevacizumab-Based Chemotherapy in Colorectal Cancer. JWatch Oncology and Hematology 2009: 2-2 [Full Text]  
• Mayer, R. J. (2009). Targeted Therapy for Advanced Colorectal Cancer -- More Is Not Always Better. NEJM 360: 623-625 [Full Text]